Martin Langner is a notable inventor based in Kundl, Tyrol, Austria. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the synthesis of complex compounds. With a total of 4 patents to his name, Langner's work has had a considerable impact on drug development.

Latest Patents

Among his latest patents is a process for preparing ceftolozane from 7-aminocephalosporanic acid (7-ACA). This invention describes a highly convergent method for the synthesis and purification of ceftolozane and its intermediates, starting from 7-ACA. Another significant patent involves the preparation of a chiral compound, specifically posaconazole. This process includes steps such as providing a mixture with a protic solvent system and a suitable base, followed by heating to obtain the desired compound.

Career Highlights

Martin Langner is currently associated with Sandoz AG, a global leader in generic pharmaceuticals and biosimilars. His work at Sandoz has allowed him to focus on innovative solutions in drug formulation and synthesis, contributing to the company's mission of improving patient access to high-quality medicines.

Collaborations

Langner has collaborated with esteemed colleagues, including Dominic De Souza and Thorsten Wilhelm. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Martin Langner's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key figure in the industry. His work continues to influence the development of essential medications, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.